Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of a Trifocal Intraocular Lens (IOL) POD L GF in Comparison With a Multifocal and a Monofocal IOL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04005651
Recruitment Status : Recruiting
First Posted : July 2, 2019
Last Update Posted : August 16, 2019
Sponsor:
Information provided by (Responsible Party):
Physiol

Brief Summary:
The objectives of the Post-Market Follow-up (PMCF) clinical investigation are to determine the safety and performance of a hydrophobic trifocal intraocular lens POD L GF in comparison with two comparator lenses: another multifocal intraocular lens (Johnson & Johnson TECNIS Symfony® Extended Range of Vision IOL); and a monofocal intraocular lens (Alcon AcrySof® IQ Monofocal IOL) through one year of post-operative assessments.

Condition or disease Intervention/treatment Phase
Aphakia, Postcataract Cataract; Eye Disease Device: POD L GF IOL Device: Symfony® IOL Device: AcrySof® IOL Not Applicable

Detailed Description:

This is a prospective, multicenter, randomized, active controlled comparative binocular Post Market Follow-up (PMCF) clinical study to demonstrate safety and efficacy between the trifocal intraocular lens POD L GF and the Johnson & Johnson TECNIS Symfony® Extended Range of Vision IOL and the Alcon AcrySof® IQ Monofocal IOL.

Patients who are scheduled to undergo cataract extraction in one or both eyes and posterior chamber intraocular lens implants may be screened for eligibility in the study and, if eligible, complete a pre-operative screening visit. Both eyes of subjects who are eligible to receive the POD L GF IOL or the Johnson & Johnson TECNIS Symfony® Extended Range of Vision IOL must be eligible to receive bilateral multifocal IOL implants. Both eyes of subjects who are eligible to receive the Alcon AcrySof® IQ Monofocal IOL must be eligible to receive bilateral monofocal IOL implants.

At the time of the first eye surgery, the subjects to be implanted with either the POD L GF (test) IOL or the Johnson & Johnson TECNIS Symfony® Extended Range of Vision (comparator) IOL will be randomized to receive either the test or comparator IOL in a 1:1 ratio. In addition, 50 subjects will be implanted with the Alcon AcrySof® IQ Monofocal IOL. All subjects will undergo bilateral IOL implantation and will receive the same brand of lenses in each eye. Second eye implantations will be delayed until 1 to 30 days after the first eye implantation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Approximately 150 subjects will be implanted bilaterally with 50 subjects implanted with the POD L GF lenses, 50 subjects implanted with the Symfony® intraocular lenses, and 50 subjects implanted with the AcrySof® monofocal lenses. The objective is to complete approximately 141 subjects through 12 month post-operative follow-up (~47 subjects in each cohort).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Post-Market Follow-up Clinical Trial to Investigate Safety and Efficacy of a Trifocal Intraocular Lens (IOL) POD L GF In Comparison With a Multifocal (TECNIS Symfony® Extended Range of Vision IOL) and a Monofocal (AcrySof® IQ Monofocal IOL)
Actual Study Start Date : May 30, 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: POD L GF
Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
Device: POD L GF IOL
Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag

Active Comparator: Symfony®
Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
Device: Symfony® IOL
Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag

Active Comparator: AcrySof®
Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
Device: AcrySof® IOL
Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag




Primary Outcome Measures :
  1. CDVA in first implanted eyes [ Time Frame: Day 120-180 both eyes ]
    Photopic monocular logMAR corrected distance visual acuity (CDVA) in first implanted eyes at Visit 4

  2. DCIVA in first implanted eyes [ Time Frame: Day 120-180 both eyes ]
    Photopic monocular logMAR intermediate visual acuity with distance correction (DCIVA) in first implanted eyes at Visit 4

  3. DCNVA in first implanted eyes [ Time Frame: Day 120-180 both eyes ]
    Photopic monocular logMAR near visual acuity with distance correction (DCNVA) in first implanted eyes at Visit 4


Secondary Outcome Measures :
  1. UDVA at Visits 3A, 3B, 4, and 5 [ Time Frame: Day 30-60 post first eye (3A), day 30-60 post second eye (3B), day 120-180 both eyes (4), day 330-420 both eyes (5) ]
    Photopic monocular logMAR uncorrected distance visual acuity (UDVA)

  2. UIVA at Visits 3A, 3B, 4, and 5 [ Time Frame: Day 30-60 post first eye (3A), day 30-60 post second eye (3B), day 120-180 both eyes (4), day 330-420 both eyes (5) ]
    Photopic monocular logMAR uncorrected intermediate visual acuity (UIVA)

  3. UNVA at Visits 3A, 3B, 4, and 5 [ Time Frame: Day 30-60 post first eye (3A), day 30-60 post second eye (3B), day 120-180 both eyes (4), day 330-420 both eyes (5) ]
    Photopic monocular logMAR uncorrected near visual acuity (UNVA)

  4. CDVA at Visits 3A, 3B, 4, and 5 [ Time Frame: Day 30-60 post first eye (3A), day 30-60 post second eye (3B), day 120-180 both eyes (4), day 330-420 both eyes (5) ]
    Photopic monocular logMAR corrected distance visual acuity (CDVA)

  5. DCIVA at Visits 3A, 3B, 4, and 5 [ Time Frame: Day 30-60 post first eye (3A), day 30-60 post second eye (3B), day 120-180 both eyes (4), day 330-420 both eyes (5) ]
    Photopic monocular logMAR intermediate visual acuity with distance correction (DCIVA)

  6. DCNVA at Visits 3A, 3B, 4, and 5 [ Time Frame: Day 30-60 post first eye (3A), day 30-60 post second eye (3B), day 120-180 both eyes (4), day 330-420 both eyes (5) ]
    Photopic monocular logMAR corrected near visual acuity with distance correction (DCNVA)

  7. Quality of Vision Questionnaire (QoV) quality of vision at Visit 4 [ Time Frame: Day 120-180 both eyes ]
    Quality of vision based on response to each question in the Quality of Vision (QoV) questionnaire at Visit 4. Answer is a choice of 4 options, the first being the least and the fourth being the most based on question type, i.e. "never" to "very often" or "not at all" to "severe".

  8. Near Activity Visual Questionnaire (NAVQ) quality of vision at Visit 4 [ Time Frame: Day 120-180 both eyes ]
    Quality of vision based on response (choice of 0-3 with 0 meaning no difficulty and 3 meaning extreme difficulty) to each question in the Near Activity Visual Questionnaire (NAVQ) at Visit 4.


Other Outcome Measures:
  1. Safety Endpoint: Rates of AEs (Adverse Events) [ Time Frame: Enrollment (Day -30 to -1) through study exit or Visit 5 (Day 330 to 420 both eyes), whichever comes first ]
    Rates of posterior chamber IOL adverse events compared to the ISO Safety and Performance Endpoint (SPE) rates as described in International Organization for Standardization (ISO) 11979-7

  2. Safety Endpoint: Optical and Visual Symptoms Assessed with NAVQ [ Time Frame: Visit 4 (Day 120 to 180 both eyes) ]
    Subject questionnaire frequency of optical and visual symptoms as reported in NAVQ

  3. Safety Endpoint: Optical and Visual Symptoms Assessed with QoV questionnaire [ Time Frame: Visit 4 (Day 120 to 180 both eyes) ]
    Subject questionnaire frequency of optical and visual symptoms as reported in QOV questionnaire

  4. Safety Endpoint: Secondary Surgical Interventions [ Time Frame: Operative Visit (Day 0) through study exit or Visit 5 (Day 330 to 420 both eyes), whichever comes first ]
    Rates of device-related secondary surgical interventions related to the POD L GF trifocal IOL

  5. Safety Endpoint: Serious Adverse Events [ Time Frame: Day 330 to 420 both eyes ]
    The rate of serious adverse events related to teh POD L GF trifocal IOL in first implanted eyes through Visit 5



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female adults ages 45 or older on the day of screening who have cataract(s) in one or both eyes
  • Capability to understand and sign an Ethics Committee (EC) approved informed consent form and privacy authorization
  • Corrected visual acuity projected by potential acuity meter (PAM) testing or other potential visual acuity test procedure to be better than 20/32 after intraocular lens implantation
  • Clear intraocular media other than cataract
  • Calculated IOL power is within the range of the study IOLs
  • Dilated pupil size large enough to visualize IOL axis markings postoperatively
  • Willing and able to conform to the study requirements

Exclusion Criteria:

  • Subjects with diagnosed degenerative visual disoerders (e.g., macular degeneration or other retinal or optic disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse
  • Subjects with age-related macular degeneration (AMD) suspicious eyes as determined by optical coherence tomography (OCT) examination
  • Subjects who may be expected to require retinal laser treatment during the course of the study or at a greater risk of developing cystoid macular edema
  • Greater than 1 diopter of pre-operative corneal astigmatism or any irregular astigmatism
  • Previous intraocular or corneal surgery
  • Traumatic cataract
  • History or presence of macular edema
  • Pregnant,lactating or, if able to bear children, unwilling to use medically acceptable birth control over the course of the study
  • Concurrent or previous (within 30 days) participation in another drug or device investigation
  • Instability of keratometry or biometry measurements
  • Ocular hypertension or glaucoma
  • Significant dry eye
  • Unsuitable for study participation for any other reason, as determined by Investigator's clinical judgement (reason to be documented on eCRF)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04005651


Contacts
Layout table for location contacts
Contact: Jochen Kandulla +49 157 862 75 281 J.Kandulla@physiol.be
Contact: Rebecca McQuaid +32 04 361 45 32 r.mcquaid@physiol.be

Locations
Layout table for location information
France
OphtALLIANCE Clinique Jules Verne Not yet recruiting
Nantes, France, 44300
Contact: Tanguy Bizeau    +33 645096083    t.bizeau@ophtalliance.fr   
Principal Investigator: Camille Bosc, MD         
Germany
Augenklinik Ahaus Not yet recruiting
Ahaus, Germany, 48683
Contact: Matthias Mueller    +49 2561 9555 247    m.mueller@augenklinik.de   
Principal Investigator: Matthias Gerl, MD         
Internationale Innovative Ophthalmochirgie Not yet recruiting
Düsseldorf, Germany, 40212
Contact: Mücella Kirca    49-211-58675748    m.kirca@augenchirurgie.clinic   
Contact: Manusha Sathiyabalan    49-211-58675748    m.sathiyabalan@augenchirurgie.clinic   
Principal Investigator: Detlev Breyer, MD         
Sub-Investigator: Karsten Klabe, MD         
Augentagesklinik Rheine Not yet recruiting
Rheine, Germany, 48429
Contact: Rafaela Lucchesi    +49 5971 8070 960    r.lucchesi@augenklinik.de   
Principal Investigator: Florian Kretz, MD         
Spain
IOA Madrid Innova Ocular Recruiting
Madrid, Spain, 28003
Contact: Nuria Garzon    34 91 5353570    ngarzon@ioamadrid.com   
Principal Investigator: Francisco Poyales Galán, MD         
Sub-Investigator: Ricardo Pérez Izquierdo, MD         
Sponsors and Collaborators
Physiol
Investigators
Layout table for investigator information
Study Director: Christophe Pagnoulle PhysIOL s.a.
Layout table for additonal information
Responsible Party: Physiol
ClinicalTrials.gov Identifier: NCT04005651    
Other Study ID Numbers: PHY1804
First Posted: July 2, 2019    Key Record Dates
Last Update Posted: August 16, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Aphakia
Aphakia, Postcataract
Eye Diseases
Lens Diseases